Literature DB >> 26202636

Oncogenic signaling pathways and origins of tumor-initiating stem-like cells of hepatocellular carcinomas induced by hepatitis C virus, alcohol and/or obesity.

Chia-Lin Chen1, Hidekazu Tsukamoto2,3, Keigo Machida4,5.   

Abstract

This review article discusses the importance and oncogenic signaling pathways of tumor-initiating cells (TICs) in several etiologies of hepatocellular carcinomas (HCCs) induced by hepatitis C virus (HCV), alcohol, obesity and/or chemicals. Stem cells may be present in cancer tissue, and a hierarchy of cells is formed, as is the case for normal tissue. Tumor formation, growth and propagation are maintained by a small proportion of cells with stem cell-like properties. TICs are present in alcohol-fed HCV transgenic mice, diethylnitrosamine/phenobarbital-treated mice (chemical carcinogenesis) and Spnb2 +/- mice (defective TGF-β signal). Alcohol/obesity-associated endotoxemia induces the stem cell marker Nanog through TLR4 signaling to generate TICs and liver tumors in several HCC models. The oncogenic pathway (such as the STAT3 and TLR4-NANOG pathway) and mechanism of generation of TICs of HCCs associated with HCV, alcohol and obesity are discussed. Understanding the molecular stemness signaling and cellular hierarchy and defining key TIC-specific genes will accelerate the development of novel biomarkers and treatment strategies. This review highlights recent advances in understanding the pathogenesis of liver TICs and discusses unanswered questions about the concept of liver TICs. (This project was supported by NIH grants 1R01AA018857 and P50AA11999).

Entities:  

Keywords:  Alcohol; Hepatitis C virus; Hepatocellular carcinoma; Nanog; TLR4; Tumor-initiating cells

Year:  2014        PMID: 26202636     DOI: 10.1007/s12072-014-9545-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  107 in total

1.  Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.

Authors:  Juanjuan Shan; Junjie Shen; Limei Liu; Feng Xia; Chuan Xu; Guangjie Duan; Yanmin Xu; Qinghua Ma; Zhi Yang; Qianzhen Zhang; Leina Ma; Jia Liu; Senlin Xu; Xiaochu Yan; Ping Bie; Youhong Cui; Xiu-wu Bian; Cheng Qian
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

2.  Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells.

Authors:  Douglas Edmund Feldman; Chialin Chen; Vasu Punj; Hidekazu Tsukamoto; Keigo Machida
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-29       Impact factor: 11.205

Review 3.  Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  S Sell; H A Dunsford
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

4.  Significance of circulating endothelial progenitor cells in hepatocellular carcinoma.

Authors:  Joanna W Y Ho; Roberta W C Pang; Cecilia Lau; Chris K Sun; Wan Ching Yu; Sheung Tat Fan; Ronnie T P Poon
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

5.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

6.  Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.

Authors:  W Song; H Li; K Tao; R Li; Z Song; Q Zhao; F Zhang; K Dou
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

7.  Isolation, culture and immortalisation of hepatic oval cells from adult mice fed a choline-deficient, ethionine-supplemented diet.

Authors:  Janina E E Tirnitz-Parker; Joanne N Tonkin; Belinda Knight; John K Olynyk; George C T Yeoh
Journal:  Int J Biochem Cell Biol       Date:  2007-06-29       Impact factor: 5.085

8.  Ethanol inhibition: the humoral and cellular immune response to hepatitis C virus NS5 protein after genetic immunization.

Authors:  J Encke; J R Wands
Journal:  Alcohol Clin Exp Res       Date:  2000-07       Impact factor: 3.455

Review 9.  Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.

Authors:  Ying-Chun Shen; Chiun Hsu; Ann-Lii Cheng
Journal:  J Gastroenterol       Date:  2010-06-22       Impact factor: 6.772

Review 10.  Hepatitis C and hepatocellular carcinoma.

Authors:  F Yao; N Terrault
Journal:  Curr Treat Options Oncol       Date:  2001-12
View more
  5 in total

1.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.

Authors:  George N Ioannou; Pamela Green; Elliott Lowy; Elijah J Mun; Kristin Berry
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

2.  Soy protein isolate inhibits hepatic tumor promotion in mice fed a high-fat liquid diet.

Authors:  Kelly E Mercer; Casey F Pulliam; Kim B Pedersen; Leah Hennings; Martin Jj Ronis
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

Review 3.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

Review 4.  IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.

Authors:  Junnv Xu; Haifeng Lin; Gang Wu; Mingyue Zhu; Mengsen Li
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

5.  Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC.

Authors:  Sudharsana R Ande; K Hoa Nguyen; B L Grégoire Nyomba; Suresh Mishra
Journal:  Sci Rep       Date:  2016-03-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.